Altered proteins in the aging brain

Journal of Neuropathology and Experimental Neurology

Volumn 75, Issue 4, 2016, Pages 316-325

  Elobeid, Adila ^a   Libard, Sylwia ^a   Leino, Marina ^a   Popova, Svetlana N ^a   Alafuzoff, Irina ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aging; Cognition; Hyperphosphorylated s; Immunohistochemistry; Transactive response DNA binding protein 43; Synuclein; Amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BRAIN PROTEIN; HYPERPHOSPHORYLATED TAU PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; TARDBP PROTEIN, HUMAN;

ADULT; AGED; AGING; ARTICLE; AUTOPSY; BRAIN; BRAIN INFECTION; BRAIN TUMOR; BRAIN WEIGHT; CEREBROVASCULAR DISEASE; EPILEPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCUS CERULEUS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; NEUROANATOMY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAUOPATHY; TRAUMATIC BRAIN INJURY; VERY ELDERLY; AGE; ALZHEIMER DISEASE; GENETICS; LONGITUDINAL STUDY; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; DNA-BINDING PROTEINS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 84961886760     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlw002     Document Type: Article

References (57)

1. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-5
2. Agorogiannis EI, Agorogiannis GI, Papadimitriou A, et al. Protein misfold-ing in neurodegenerative diseases. Neuropathol Appl Neurobiol 2004;30: 215-24
3. Thal DR, Rüb U, Orantes M, et al. Phases of Ab-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
4. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
5. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005;65:1863-72
6. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immuno-cytochemistry. Acta Neuropathol 2006;112:389-404
7. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3
8. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuro-pathol Exp Neurol 2011;70:960-9
9. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011;121:171-81
10. Josephs KA, Murray ME, Whitwell JL, et al. Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol 2014;127:441-50
11. Alafuzoff I, Pikkarainen M, Al-Sarraj S, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: A study of the Brain-Net Europe Consortium. J Neuropathol Exp Neurol 2006;65:740-57
12. Alafuzoff I, Ince PG, Arzberger T, et al. Staging/typing of Lewy body related a-synuclein pathology: A study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:635-52
13. Alafuzoff I, Thal DR, Arzberger T, et al. Assessment of b-amyloid deposits in human brain: A study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:309-20
14. Alafuzoff I, Pikkarainen M, Neumann M, et al. Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: An inter-laboratory study by the BrainNet Europe consortium. J Neural Transm 2015;122:957-72
15. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122:111-3
16. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20-38
17. Davis DG, Schmitt FA, Wekstein DR, et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neu-rol 1999;58:376-88
18. Parkkinen L, Soininen H, Laakso M, et al. a-Synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001;27:314-25
19. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95
20. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of a-synu-clein pathology in unimpaired aging and Alzheimer disease. J Neuropa-thol Exp Neurol 2003;62:363-7
21. Jellinger KA. Lewy body-related a-synucleinopathy in the aged human brain. J Neural Transm 2004;111:1219-35
22. Mikolaenko I, Pletnikova O, Kawas CH, et al. a-Synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 2005;64:156-62
23. Nakashima-Yasuda H, Uryu K, Robinson J, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007; 114:221-9
24. White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: A summary report from the Honolulu-Asia aging study. J Alzheimers Dis 2009;18:713-25
25. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nonde-mented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-36
26. Aho L, Karkola K, Juusela J, et al. Heavy alcohol consumption and neuropath-ological lesions: A post-mortem human study. J Neurosci Res 2009;87:2786-92
27. Markesbery WR, Jicha GA, Liu H, et al. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009;68:816-22
28. Bennett DA, Wilson RS, Boyle P, et al. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012;72:599-609
29. Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: Correlation with argyr-ophilic grains but not other concomitant pathologies. Acta Neuropathol 2013;126:51-7
30. Boyle PA, Yu L, Wilson RS, et al. Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neu-rosci 2013;5:50-9
31. Kovacs GG, Milenkovic I, Wöhrer A, et al. Non-Alzheimer neurodegen-erative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol 2013;126:365-84
32. Dugger BN, Hentz JG, Adler CH, et al. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropa-thol Exp Neurol 2014;73:244-52
33. Uchino A, Takao M, Hatsuta H, et al. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun 2015;3:35
34. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tau-opathy (PART): A common pathology associated with human aging. Acta Neuropathol 2014;128:755-66
35. Duyckaerts C, Braak H, Brion JP, et al. PART is part of Alzheimer disease. Acta Neuropathol 2015;129:749-56
36. Rauramaa T, Pikkarainen M, Englund E, et al. Consensus recommendations on pathologic changes in the hippocampus: A postmortem multi-center inter-rater study. J Neuropathol Exp Neurol 2013;72:452-61
37. Thal DR, Ghebremedhin E, Rüb U, et al. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002;61:282-93
38. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13
39. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012;123:1-11
40. Nelson PT, Abner EL, Schmitt FA, et al. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol 2009;68:774-84
41. Elobeid A, Rantakömi S, Soininen H, et al. Alzheimer's disease-related plaques in nondemented subjects. Alzheimers Dement 2014;10:522-9
42. Whalley LJ, Deary IJ, Appleton CL, et al. Cognitive reserve and the neu-robiology of cognitive aging. Ageing Res Rev 2004;3:369-82
43. Tucker AM, Stern Y. Cognitive reserve in aging. Curr Alzheimer Res 2011;8:354-60
44. Steffener J, Stern Y. Exploring the neural basis of cognitive reserve in aging. Biochim Biophys Acta 2012;1822:467-73
45. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-9
46. Nelson PT, Jicha GA, Schmitt FA, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neu-ropathol Exp Neurol 2007;66:1136-46
47. Erten-Lyons D, Woltjer RL, Dodge H, et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-60
48. Abner EL, Kryscio RJ, Schmitt FA, et al. "End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: Fact or fiction? J Alzheimers Dis 2011;25:445-53
49. Pikkarainen M, Martikainen P, Alafuzoff I. The effect of prolonged fixation time on immunohistochemical staining of common neurodegenera-tive disease markers. J Neuropathol Exp Neurol 2010;69:40-52
50. Kovacs GG, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated a-synuclein reveals extensive brain pathology. Acta Neuropathol 2012;124:37-50
51. Wakisaka Y, Furuta A, Tanizaki Y, et al. Age-associated prevalence and risk factors of Lewy body pathology in a general population: The Hisayama study. Acta Neuropathol 2003;106:374-82
52. Leverenz JB, Hamilton R, Tsuang DW, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 2008;18:220-4
53. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of id-iopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52
54. Del Tredici K, Rüb U, De Vos RA, et al. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-26
55. Ozawa T, Revesz T, Paviour D, et al. Difference in MSA phenotype distribution between populations: Genetics or environment? J Parkinsons Dis 2012;2:7-18
56. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41: 479-86
57. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59